<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327522</url>
  </required_header>
  <id_info>
    <org_study_id>106962</org_study_id>
    <nct_id>NCT00327522</nct_id>
    <nct_alias>NCT00309153</nct_alias>
  </id_info>
  <brief_title>Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.</brief_title>
  <official_title>An Open, Phase I/II Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 11PCV Vaccine Given as a 2-Dose Vaccination in Adults Aged 18-40 Years Old.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of two doses of GSK
      Biologicals' 11 PCV vaccine when given to healthy subjects aged 18 to 40 years .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is open and subjects will receive two vaccine doses of GSK Biologicals' 11 PCV
      vaccine. Five blood samples will be taken: prior to and one month after each vaccine dose,
      and 2 weeks after dose 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of solicited local &amp; general symptoms (Day 0-7) and unsolicited symptoms (Day 0-30) after vaccination. Occurrence of serious adverse events during the entire study;</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequencies of IgG PS-specific plasma cells (by B-cell ELISPOT) for 11 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) prior to &amp; 1 month post dose 1, 2 weeks &amp; 1 month post dose 2</measure>
  </primary_outcome>
  <enrollment>10</enrollment>
  <condition>Prophylactic Pneumococcal Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pneumococcal vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male or female between 18 and 40 years of age

          -  23-valent pneumococcal polysaccharide vaccine naive adults.

        Exclusion Criteria:

          -  Previous vaccination against Streptococcus pneumoniae.

          -  History of pneumonia within 3 years prior to the first vaccination

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition

          -  All malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders
             diagnosed or treated actively during the past 5 years.

          -  Subjects with documented anaemia or iron-deficiency (Hemoglobin level more than 10%
             below lower limit of normal)

          -  History of administration of an experimental/licensed vaccine containing similar
             adjuvants.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2006</study_first_submitted>
  <study_first_submitted_qc>May 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2006</study_first_posted>
  <last_update_submitted>October 9, 2008</last_update_submitted>
  <last_update_submitted_qc>October 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

